BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cell Therapy » Page 3

Cynata to Launch World’s First Phase 3 Trial with an iPSC-Derived Cell Therapeutic

By Leave a Comment

With an anticipated enrollment of 440 patients, it will be the world’s largest trial ever completed with an iPSC-derived cell therapeutic.

It’s official. Australian stem cell company Cynata Therapeutics is preparing to test its iPSC-derived cell therapeutic, CYP 004, in a Phase 3 clinical trial enrolling up to 440 patients.

Led by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC), the historic trial will assess whether Cynata’s cell therapeutic, CYP-004, has the capacity to improve patient outcomes in osteoarthritis (OA).

CYP-004 is an allogeneic, iPSC-derived mesenchymal stem cell (MSC) product derived using Cynata’s proprietary Cymerus™ technology. [Read more…]

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

By Leave a Comment

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science! [Read more…]

American Academy of Stem Cell Physicians To Host 1st Virtual Congress & Safety Panel (August 1-2, 2020)

By

While COVID-19 has caused many events to be rescheduled, a highly anticipated and sought after American Academy of Stem Cell Physicians (AASCP) meeting is back by popular demand. Over August 1-2, 2020, the AASCP will host its first virtual congress, allowing for wide-scale participation at an unprecedented scale. The Academy is expecting 5,000 attendees, as the program will be broadcasting internationally.
 [Read more…]

FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)

By

PneumoBlast™ Reduces Pathology and Lung Fluid Accumulation in Model of COVID-19

HOUSTON, May 21, 2020 — FibroGenesis announced significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19.  Mice immune systems were stimulated to enter hyper-activation mode, which causes symptoms similar to COVID-19.  Once COVID-19 simulation was achieved, administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation.  Additionally, reduction was observed from infiltration of inflammatory cells, as well as suppression of chemical mediators such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients. [Read more…]

BioInformant's World-Class Clients